Multisystem inflammatory syndrome in children: Difference between revisions
| Line 30: | Line 30: | ||
==External Links== | ==External Links== | ||
*[https:// | *[https://totalwebcasting.com/view/?func=VOFF&id=nysdoh&date=2020-05-14&seq=1 NY Webinar] | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 16:34, 18 May 2020
Background
- Some individuals may fulfill full or partial criteria for Kawasaki disease but should be reported if they meet the case definition for MIS-C
- Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection
Clinical Features
Differential Diagnosis
Evaluation
Case Definition
- An individual aged <21 years presenting with fever^, laboratory evidence of inflammation^^, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND
- No alternative plausible diagnoses; AND
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms
- ^Fever >38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours
- ^^Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin